
SAO PAULO, April 24 (Reuters) - A greater supply of raw materials and finished products in the global market due to the imposition of tariffs may represent an opportunity for long-term cost reduction for Hypera, CEO Breno de Oliveira said on Thursday.
Hypera is the largest publicly listed pharmaceutical company in Brazil.